Our 2025 database of anti-DLL3 therapeutic programmes in oncology is available for free download here.
🔬 What’s inside?
✅ 6 DLL3-targeted antibody–drug conjugate (ADC) programmes
✅ 7 bispecific and trispecific antibodies
✅ 4 CAR-T & CAR-NK programmes
✅ 1 preclinical DLL3-targeting radiotherapy (RT) programme
❌ 4 discontinued anti-DLL3 clinical trials
Featuring anti-DLL3 programmes addressing solid tumours from leading players, including:
AbbVie, Amgen, Biocytogen, Boehringer Ingelheim, Chugai Pharmaceutical, CStone Pharma, Dragonfly Therapeutics, Harpoon Therapeutics, Hengrui, IDEAYA, Legend Biotech, MediLink Therapeutics, Merck, Molecular Partners, Novartis, Orano Med, Qilu Pharmaceuticals, Roche, Shanghai Fudan-Zhangjiang BioPharma, Suzhou Suncadia Biopharmaceuticals, Stemcentrx, Zai Lab, Zymeworks, and more!